Validation of Polo-like kinase 1 as a therapeutic target in pancreatic cancer cells
Zhang C, Sun X, Ren Y, Lou Y, Zhou J, Liu M, Li D. Validation of Polo-like kinase 1 as a therapeutic target in pancreatic cancer cells. Cancer Biology & Therapy 2012, 13: 1214-1220. PMID: 22892842, PMCID: PMC3469479, DOI: 10.4161/cbt.21412.Peer-Reviewed Original ResearchConceptsPancreatic cancer cellsCancer cellsPolo-like kinase 1Human pancreatic cancer cellsChemotherapeutic drug gemcitabinePLK1 inhibitorsCombination index analysisKinase 1Pancreatic cancerClinical investigationTherapeutic targetCancer treatmentExpression levelsDrug gemcitabineValuable targetCellsTreatmentInhibitorsProliferationCritical roleMicrotubule‐binding protein CLIP‐170 is a mediator of paclitaxel sensitivity
Sun X, Li D, Yang Y, Ren Y, Li J, Wang Z, Dong B, Liu M, Zhou J. Microtubule‐binding protein CLIP‐170 is a mediator of paclitaxel sensitivity. The Journal Of Pathology 2012, 226: 666-673. PMID: 21989536, DOI: 10.1002/path.3026.Peer-Reviewed Original ResearchConceptsBreast cancerPaclitaxel sensitivityPaclitaxel-containing chemotherapyActivity of paclitaxelBreast cancer correlatesCaspase-3 activity analysisBreast cancer cell linesBreast cancer cellsAbility of paclitaxelCancer cell linesCell proliferation assaysCancer correlatesPathological responsePaclitaxelProliferation assaysCell cycle progressionCancer cellsClinical samplesMitotic indexCell linesCancerMicrotubule-dependent mechanismCycle progressionDrug paclitaxelMicrotubule-binding protein